Kishore Kumar Shil

Kishore Kumar Shil

Auto-generated profile, based on publicly available information

Kishore Kumar Shil

Department of Endocrinology Bangladesh Medical University Dhaka Bangladesh

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MHMashfiqul Hasan
Mashfiqul Hasan
NSNusrat Sultana
Nusrat Sultana
KSKishore Kumar Shil
Kishore Kumar Shil
SASayad Bin Abdus-Salam
Sayad Bin Abdus-Salam
MNMaksudur Rahman Nayem
Maksudur Rahman Nayem
MHMuhammad Abul Hasanat
Muhammad Abul Hasanat
The global distribution and frequency of maturity onset diabetes of the young (MODY) vary, necessitating investigation across diverse ethnic groups. This study aimed to investigate MODY gene variants and phenotypic characteristics among young Bangladeshi individuals with nonobese, nonautoimmune youth-onset diabetes. Fifty participants with diabetes (onset < 35 years, BMI < 25 kg/m², negative for islet autoantibodies, detectable C-peptide, and a family history of DM) and 50 young individuals with normoglycemia were enrolled. Targeted next-generation sequencing (NGS) was performed on a panel of 14 known MODY genes. Candidate MODY-gene variants were identified in 20% (10/50) of the diabetes cohort. There were 11 heterozygous missense variants across eight genes: HNF1A, PDX1, NEUROD1, KLF11, PAX4 (three variants), BLK, ABCC8 (two variants), and KCNJ11. No variants met the ACMG/AMP criteria for ‘Pathogenic’ or ‘Likely Pathogenic’ classification; all identified variants were categorized as variants of uncertain significance (VUS). No significant phenotypic differences were observed between individuals with diabetes who carried identified variants and those who did not. In conclusion, this study identified candidate MODY variants (all classified as VUS) in one-fifth of the Bangladeshi nonobese, nonautoimmune youth-onset diabetes cohort. These findings provide a preliminary indication of a distinct genetic pattern characterized by a low frequency of common variants and a relative abundance of variants in rare MODY-associated genes. These findings are hypothesis-generating and highlight potential genetic targets for future functional validation to confirm pathogenicity and to support definitive MODY diagnoses.

1 June 2025 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
KSKishore Kumar Shil
Kishore Kumar Shil
MHMashfiqul Hasan
Mashfiqul Hasan
NSNusrat Sultana
Nusrat Sultana
SSSayad Bin Abdus Salam
Sayad Bin Abdus Salam
SMSyeda Nazlee Mostafa
Syeda Nazlee Mostafa
MHMuhammad Abul Hasanat
Muhammad Abul Hasanat
Background: Obesity and insulin resistance are the key pathogenic factors for both metabolic dysfunction-associated steatotic liver disease (MASLD) and type-2 diabetes (T2DM), and their rising prevalence is driving an increase in MASLD cases. Objective: To assess the presence of fatty liver disease by ultrasonography (USG) and to find out its predictors in newly diagnosed young-onset T2DM. Methods: This cross-sectional study enrolled 137 newly diagnosed adolescents and young adult T2DM subjects (aged 10– 34 years) by non-probability purposive sampling at a tertiary hospital in Bangladesh. Individuals with a history of alcoholism, pregnancy, infections, endocrinopathies, genetic disorders, or drugs that can cause fatty liver were excluded. Fatty liver was assessed by ultrasonography. C-peptide, anti-GAD65, and anti-IA2 antibodies were measured by chemiluminescent immunoassay, and anti-ZnT8 antibodies by ELISA. Results: Among 137 newly diagnosed adolescents and young adult T2DM patients, 92 (68.1%) had fatty liver on ultrasonography— 58 (63%) with grade 1 and 34 (37%) with grade 2. Most were overweight/obese (67.2%), had central obesity (88.3%), and reported low physical activity (68.6%). Fatty liver was significantly associated with older age, higher BMI, WHR, and a positive family history of diabetes. On multivariate analysis, age (OR 1.14, 95% CI 1.04– 1.25, p=0.004), positive family history of DM (OR 3.21, 95% CI 1.29– 8.22, p=0.012), acanthosis nigricans (OR: 5.05, 95% CI 1.59– 16.04, p=0.006), and fasting C-peptide levels (OR 1.46, 95% CI 1.10– 1.92; p = 0.007) were significant predictors of fatty liver. Conclusion: Fatty liver is highly prevalent in young-onset T2DM at diagnosis. Age, a positive family history of diabetes, acanthosis nigricans, and elevated fasting C-peptide levels are strong predictors. Routine use of ultrasonography may facilitate early detection and management of liver disease in this population.

24 August 2025 in Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh
Verified
Journal Article
Open access
PDF file
KSKishore Kumar Shil
Kishore Kumar Shil
SASayad Bin Abdus-Salam
Sayad Bin Abdus-Salam
NSNusrat Sultana
Nusrat Sultana
Type 5 Diabetes Mellitus (T5DM), also known as Malnutrition-Related Diabetes Mellitus (MRDM), is a distinct and underrecognized form of diabetes associated with chronic undernutrition. Although considered rare, it is not uncommon in developing countries like Bangladesh, where malnutrition remains a widespread issue. Diabetes mellitus, a multifactorial endocrine disorder, is associated with both chronic undernutrition and obesity. Malnutrition often involves deficiencies in macro- and micronutrients in prenatal or postnatal life, unhealthy lifestyle behaviors, and low socioeconomic status. Numerous clinical studies have highlighted the connection between malnutrition and diabetes. Diagnostic challenges, overlapping symptoms, and an unclear causal relationship between malnutrition and diabetes hinder its classification and management. Current global diabetes frameworks inadequately address T5DM, contributing to misdiagnosis and delayed treatment. Malnutrition predominantly results in persistent insulin deficiency, glucose intolerance, and insulin resistance, thereby increasing the risk of developing diabetes. Further research is essential to refine the diagnostic criteria, elucidate the underlying pathophysiology, and assess the clinical and public health benefits of formally recognizing T5DM as a distinct subtype of diabetes mellitus. J Assoc Clin Endocrinol Diabetol Bangladesh, July 2025;4(2): 72-79

8 January 2026 in Health Science Reports
Verified
Journal Article
Open access
RHRakibul Hasan
Rakibul Hasan
KSKishore Kumar Shil
Kishore Kumar Shil
Md Shahed-MorshedMd Shahed-Morshed
Md Shahed-Morshed
Background and Aims: Semaglutide, a once‐weekly injectable glucagon‐like peptide, showed double‐digit weight reduction with an acceptable safety profile in clinical trials and real‐world studies. The efficacy and safety of non‐comparable biotherapeutic (NCB) semaglutide are not adequately reported. Our study aimed to assess the weight reduction and adverse effects of an NCB semaglutide in a real‐world setting. Methods: This retrospective observational study conducted at three urban private practice settings collected data from an electronic record of 87 people with obesity [age (years): 32.2 ± 11.6, BMI (kg/m 2 ): 34.4 ± 4.3, mean ± SD, Female 73(83.9%)] between 7 February 2023 and 31 December 2024 treated with variable doses and durations of NCB semaglutide. The dose, the number of injections administered between visits, weight, side effects, the decision regarding dosing, and patient compliance were recorded at each follow‐up. Results: The maximum prescribed doses of NCB semaglutide were 0.5 mg per week in 65 (74.7%) of participants, followed by 1.0 mg and 1.7 mg per week in 17 (19.5%) and 5 (5.7%) participants, respectively. Considering available participants of all visits ( n = 192), 28 (14.6%) participants were lost to follow‐up, NCB semaglutide was ongoing in 32 (16.7%), 23 (12.0%) patients discontinued NCB semaglutide, and one patient died. The mean weight loss was 6.9% and 13.3% at 12 and 24 weeks of follow‐up, respectively. The frequency of reported any side effects and major adverse effects was 59.4% and 9.9%, respectively. Conclusion: A locally available NCB semaglutide in an uncontrolled, real‐world setting showed acceptable weight loss and safety profiles among people with obesity.

5 June 2026 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
MHMashfiqul Hasan
Mashfiqul Hasan
NSNusrat Sultana
Nusrat Sultana
KSKishore Kumar Shil
Kishore Kumar Shil
SSSayad Bin Abdus Salam
Sayad Bin Abdus Salam
KAKoushik Ashraf
Koushik Ashraf
MHMuhammad Abul Hasanat
Muhammad Abul Hasanat
Background: Young‐onset diabetes in South Asians frequently manifests in lean individuals, but the metabolic drivers of this phenotype remain poorlycharacterised. Objective: This study aimed to evaluate the clinical, biochemical, and insulin‐related indices of lean, non‐autoimmune young‐onset diabetes mellitus (DM) among Bangladeshi young adults. Methods: This comparative cross‐sectional study (2023–2024) enrolled 373 participants (aged 18–34 years) categorised into four groups based on glycemic status and body mass index (BMI): Lean DM ( n = 53), obese DM ( n = 125), lean non‐DM ( n = 78), and obese non‐DM ( n = 117) from the Young‐diabetes Clinic of the Department of Endocrinology, Bangladesh Medical University, Dhaka after excluding those with positive islet autoantibodies, low C‐peptide, pancreatic pathology, and monogenic variants. β‐cell function (HOMA2‐B) and insulin resistance (HOMA2‐IR) were quantified using the HOMA2 C‐peptide calculator. Results: Lean DM participants were comparable to other groups in age, sex, and family history, though smoking was more prevalent than in lean controls ( p < 0.05). Prevalence of central obesity and blood pressure levels of lean DM were similar to those of lean controls, but the lipid profile was comparable to that of obese DM. The median HbA1c was higher in lean DM than in obese DM (11.6% vs. 8.5%; p < 0.001), while their median HOMA2‐B was the lowest across all other groups ( p < 0.01). The HOMA2 − IR in lean DM was lower than in obese DM but significantly higher than in lean controls and mirrored the resistance seen in the obese non‐DM group ( p < 0.001). Conclusion: Lean young‐onset diabetes in Bangladesh appears to be a phenotype of disproportionate insulin secretory defect with only modest insulin resistance and metabolic dysfunction. These features highlight the need for targeted screening and individualised management.

29 October 2025 in Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh
Verified
Journal Article
Open access
PDF file
KSKishore Kumar Shil
Kishore Kumar Shil
Type 5 Diabetes Mellitus (T5DM), also known as malnutrition-related diabetes, is a largely neglected and under-recognized form of dysglycemia, predominantly affecting tropical and subtropical regions. Unlike type 1 and type 2 diabetes, T5DM often develops in the context of chronic undernutrition, early-life malnutrition, and socio-economic deprivation, leading to a unique clinical and metabolic profile. Its diagnosis remains challenging due to overlapping features with other diabetes types, heterogeneous presentations, and the lack of standardized diagnostic criteria, often resulting in underdiagnosis or mismanagement. The pathophysiology of T5DM is multifactorial. Chronic nutritional deficiencies lead to impaired pancreatic beta-cell development and long-term insulin secretory defects. Concurrently, patients exhibit variable degrees of insulin resistance, altered glucose metabolism, and enhanced susceptibility to oxidative stress and inflammatory pathways. Emerging evidence suggests a role of micronutrient deficiencies (e.g., zinc, vitamin D, thiamine) and persistent metabolic programming from early-life malnutrition, which together exacerbate dysglycemia. Developing countries, particularly in South Asia—including Bangladesh—bear a disproportionate burden of T5DM, making awareness, early diagnosis, and context-specific interventions critical. Recent advances in biomarkers, metabolic imaging, and therapeutic strategies offer promise for better characterization and individualized management. Recognizing and addressing this hidden face of diabetes is essential for improving patient outcomes, guiding public health strategies, and mitigating the growing impact of dysglycemia in vulnerable populations. [J Assoc Clin Endocrinol Diabetol Bangladesh, 2025;4(Suppl 1): S26]